 Jennifer Soep
Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Purpura, Schoenlein-Henoch | 1 | 2018 | 11 | 0.790 |
Why?
| | Lupus Erythematosus, Systemic | 6 | 2013 | 250 | 0.730 |
Why?
| | Coronary Artery Disease | 1 | 2018 | 668 | 0.490 |
Why?
| | Atherosclerosis | 3 | 2013 | 271 | 0.290 |
Why?
| | Arteriosclerosis | 1 | 2004 | 115 | 0.280 |
Why?
| | Education, Medical, Undergraduate | 4 | 2020 | 139 | 0.280 |
Why?
| | Clinical Competence | 3 | 2020 | 873 | 0.270 |
Why?
| | Heptanoic Acids | 2 | 2013 | 72 | 0.250 |
Why?
| | Antirheumatic Agents | 2 | 2018 | 250 | 0.240 |
Why?
| | Pyrroles | 2 | 2013 | 198 | 0.230 |
Why?
| | Internship and Residency | 2 | 2020 | 885 | 0.220 |
Why?
| | Models, Psychological | 1 | 2020 | 343 | 0.190 |
Why?
| | Infliximab | 1 | 2018 | 86 | 0.190 |
Why?
| | Competency-Based Education | 1 | 2018 | 53 | 0.180 |
Why?
| | Pediatrics | 2 | 2018 | 1052 | 0.180 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2018 | 136 | 0.180 |
Why?
| | Narration | 1 | 2017 | 48 | 0.170 |
Why?
| | Learning | 2 | 2018 | 350 | 0.170 |
Why?
| | Endothelium, Vascular | 1 | 2004 | 959 | 0.170 |
Why?
| | Coronary Vessels | 1 | 2018 | 263 | 0.160 |
Why?
| | Aspirin | 1 | 2018 | 283 | 0.160 |
Why?
| | C-Reactive Protein | 3 | 2013 | 358 | 0.160 |
Why?
| | Child | 12 | 2018 | 16454 | 0.160 |
Why?
| | Diagnosis, Differential | 2 | 2018 | 1453 | 0.160 |
Why?
| | Students, Medical | 2 | 2017 | 203 | 0.150 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 329 | 0.150 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 83 | 0.150 |
Why?
| | Echocardiography | 1 | 2018 | 629 | 0.150 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2014 | 89 | 0.140 |
Why?
| | Skin | 1 | 2018 | 685 | 0.130 |
Why?
| | Capillaries | 1 | 2013 | 114 | 0.130 |
Why?
| | Biomarkers | 4 | 2013 | 3311 | 0.130 |
Why?
| | Vasculitis | 1 | 2013 | 87 | 0.130 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 43 | 0.130 |
Why?
| | Lupus Nephritis | 1 | 2012 | 45 | 0.120 |
Why?
| | Twins, Monozygotic | 1 | 2013 | 284 | 0.120 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2011 | 17 | 0.120 |
Why?
| | Remission Induction | 1 | 2012 | 273 | 0.120 |
Why?
| | Connective Tissue Diseases | 1 | 2011 | 50 | 0.110 |
Why?
| | Potassium Channels | 1 | 2011 | 132 | 0.110 |
Why?
| | Pulmonary Alveoli | 1 | 2013 | 378 | 0.110 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 205 | 0.110 |
Why?
| | Anticholesteremic Agents | 1 | 2012 | 138 | 0.110 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 221 | 0.110 |
Why?
| | Lung Diseases | 2 | 2013 | 710 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2012 | 166 | 0.100 |
Why?
| | Thrombophilia | 1 | 2009 | 73 | 0.100 |
Why?
| | Hemorrhage | 1 | 2013 | 533 | 0.100 |
Why?
| | Carotid Artery, Common | 1 | 2009 | 27 | 0.100 |
Why?
| | Arthritis, Juvenile | 1 | 2009 | 38 | 0.100 |
Why?
| | Tunica Intima | 1 | 2009 | 93 | 0.100 |
Why?
| | Male | 14 | 2018 | 59744 | 0.100 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 391 | 0.100 |
Why?
| | Lipoproteins, LDL | 2 | 2010 | 144 | 0.100 |
Why?
| | Adolescent | 11 | 2013 | 18076 | 0.090 |
Why?
| | Cholesterol, LDL | 2 | 2013 | 310 | 0.090 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 283 | 0.090 |
Why?
| | Age of Onset | 2 | 2009 | 501 | 0.090 |
Why?
| | Humans | 18 | 2018 | 108073 | 0.090 |
Why?
| | Brain Ischemia | 1 | 2009 | 262 | 0.080 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 947 | 0.080 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 858 | 0.080 |
Why?
| | Chilblains | 1 | 2005 | 2 | 0.080 |
Why?
| | Stroke | 1 | 2012 | 872 | 0.080 |
Why?
| | Apolipoprotein A-I | 1 | 2004 | 27 | 0.070 |
Why?
| | Antigen-Antibody Complex | 1 | 2004 | 80 | 0.070 |
Why?
| | Risk Factors | 5 | 2012 | 8712 | 0.070 |
Why?
| | Cholesterol, HDL | 1 | 2004 | 233 | 0.070 |
Why?
| | Faculty, Medical | 2 | 2017 | 236 | 0.070 |
Why?
| | Double-Blind Method | 3 | 2013 | 1690 | 0.070 |
Why?
| | Female | 13 | 2014 | 61236 | 0.060 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2013 | 65 | 0.060 |
Why?
| | Hypertension, Pulmonary | 1 | 2011 | 1674 | 0.050 |
Why?
| | Prospective Studies | 4 | 2013 | 5904 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2004 | 768 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2010 | 1616 | 0.050 |
Why?
| | Inflammation | 1 | 2009 | 2233 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2013 | 8857 | 0.040 |
Why?
| | Schools, Medical | 1 | 2018 | 115 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2004 | 3294 | 0.040 |
Why?
| | Colorado | 3 | 2012 | 4510 | 0.040 |
Why?
| | Young Adult | 4 | 2012 | 10635 | 0.040 |
Why?
| | Disease Progression | 2 | 2013 | 2431 | 0.040 |
Why?
| | Infant | 3 | 2013 | 7815 | 0.040 |
Why?
| | Time Factors | 2 | 2020 | 7090 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 352 | 0.030 |
Why?
| | Prognosis | 2 | 2012 | 3402 | 0.030 |
Why?
| | Focus Groups | 1 | 2014 | 349 | 0.030 |
Why?
| | Antiphospholipid Syndrome | 1 | 2012 | 26 | 0.030 |
Why?
| | Enoxaparin | 1 | 2012 | 35 | 0.030 |
Why?
| | Child, Preschool | 3 | 2012 | 9399 | 0.030 |
Why?
| | Polysaccharides | 1 | 2012 | 79 | 0.030 |
Why?
| | Curriculum | 1 | 2018 | 753 | 0.030 |
Why?
| | Puberty | 1 | 2013 | 144 | 0.030 |
Why?
| | Immunomodulation | 1 | 2012 | 81 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2012 | 309 | 0.030 |
Why?
| | Carotid Arteries | 1 | 2013 | 194 | 0.030 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 105 | 0.030 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2011 | 70 | 0.030 |
Why?
| | Syndrome | 1 | 2011 | 330 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2011 | 4794 | 0.030 |
Why?
| | Rituximab | 1 | 2011 | 157 | 0.030 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 153 | 0.030 |
Why?
| | Lipoprotein(a) | 1 | 2010 | 45 | 0.030 |
Why?
| | Lipoproteins, HDL | 1 | 2010 | 87 | 0.030 |
Why?
| | Qualitative Research | 1 | 2014 | 684 | 0.030 |
Why?
| | Placebos | 1 | 2010 | 223 | 0.030 |
Why?
| | Echocardiography, Doppler | 1 | 2011 | 129 | 0.030 |
Why?
| | Factor VIII | 1 | 2009 | 53 | 0.030 |
Why?
| | Montana | 1 | 2009 | 20 | 0.030 |
Why?
| | Recurrence | 1 | 2012 | 974 | 0.030 |
Why?
| | Blood Sedimentation | 1 | 2009 | 32 | 0.030 |
Why?
| | Utah | 1 | 2009 | 63 | 0.030 |
Why?
| | Azathioprine | 1 | 2009 | 48 | 0.030 |
Why?
| | Drug Tolerance | 1 | 2009 | 157 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2011 | 228 | 0.020 |
Why?
| | Cholesterol | 1 | 2010 | 381 | 0.020 |
Why?
| | Lipoproteins | 1 | 2009 | 168 | 0.020 |
Why?
| | Prednisone | 1 | 2009 | 234 | 0.020 |
Why?
| | Receptors, Interleukin-1 | 1 | 2009 | 243 | 0.020 |
Why?
| | Triglycerides | 1 | 2010 | 535 | 0.020 |
Why?
| | Anticoagulants | 1 | 2012 | 492 | 0.020 |
Why?
| | Lipids | 1 | 2012 | 598 | 0.020 |
Why?
| | Creatinine | 1 | 2009 | 436 | 0.020 |
Why?
| | Adult | 2 | 2005 | 31195 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2009 | 480 | 0.020 |
Why?
| | Age Factors | 1 | 2013 | 3275 | 0.020 |
Why?
| | Ultrasonography | 1 | 2009 | 751 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2009 | 10506 | 0.020 |
Why?
| | Cytokines | 1 | 2012 | 1894 | 0.020 |
Why?
| | Autoantibodies | 1 | 2011 | 1145 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2258 | 0.020 |
Why?
| | Incidence | 1 | 2009 | 2352 | 0.020 |
Why?
| | Sex Factors | 1 | 2009 | 1930 | 0.020 |
Why?
| | Cohort Studies | 1 | 2012 | 4740 | 0.020 |
Why?
| | Acute Disease | 1 | 2005 | 986 | 0.020 |
Why?
| | United States | 1 | 2018 | 11417 | 0.020 |
Why?
| | Body Mass Index | 1 | 2009 | 2044 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2010 | 3898 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2378 | 0.010 |
Why?
|
|
Soep's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|